CNTB News & Events

Connect Biopharma highlighted new mechanism of action data for rademikibart and outlined its priorities for 2026. Development Highlights: New mechanism of action data supports the use of rademikibart in combination with standard of care beta-agonists to reverse acute exacerbations and for maintenance therapy in asthma and COPD; Initiated Phase 1b clinical pharmacology study with IV rademikibart to evaluate opportunity to reverse bronchoconstriction even more quickly than subcutaneous dosing; expect to report topline results in the first quarter of 2026; Recruitment of participants into the Phase 2 Seabreeze STAT asthma and Seabreeze STAT COPD studies evaluating the safety and efficacy of rademikibart as an adjunct treatment for acute exacerbations is ongoing with topline data from both studies expected in mid-2026.

Lake Street analyst Thomas Flaten initiated coverage of Connect Biopharma with a Buy rating and $9 price target. Shares have recently gained traction in the market in recognition of the upcoming Seabreeze STAT readouts and the upside they may deliver to shareholders, argues the analyst, who sees "significant headroom for shares beyond today" ahead of readouts due in the first half of 2026 and as the long-term potential of rademikibart "becomes more fully understood."

Reports Q3 revenue $16k vs $1.2M last year. "Throughout 2025, we have worked diligently to position Connect for success by activating our Phase 2 Seabreeze STAT studies of rademikibart in participants experiencing acute asthma and chronic obstructive pulmonary disease exacerbations and to further solidify our U.S. presence," said Barry Quart, Pharm.D., CEO and Director of Connect Biopharma. "As we look to the remainder of the year, we are focused on patient recruitment and clinical execution in both studies and expect to deliver topline data in the first half of 2026. We continue to work closely with Simcere in advancing rademikibart in China, making strong progress as Simcere submitted its New Drug Application for the treatment of atopic dermatitis to China's National Medical Products Administration in July 2025 and continues to progress its Phase 3 asthma maintenance study."